 | |
- close
- close
|
PR Newswire
Oct 29
Comment
SAN CARLOS, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2009 on Wednesday, November 4, 2009, after the close of U.S.-based financial
PR Newswire
Oct 29
Comment
PASADENA, Calif., Oct. 29 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), Landlord of Choice to the Life Science Industry®, today provided an update highlighting recent accomplishments. Alexandria announced the delivery of a
Stock Blog Hub
Oct 28
Comment
by Marc Lichtenfeld, Healthcare Expert
Wednesday, October 28, 2009: Issue #1125
When it comes to investing, how do you find the “Holy Grail?” Does it even exist?
Over my 19 years of stock market experience, I’ve searched high and...
PR Newswire
Oct 27
Comment
SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- Data from a phase II study demonstrated that oral NKTR-118 improved lower gastrointestinal dysfunction by increasing the frequency of bowel movements in patients with opioid-induced constipation, while
Stock Blog Hub
Oct 13
Comment
Recently, Nektar Therapeutics (NKTR) presented data from its phase II trial of oral NKTR-118, meant for the treatment of opioid-induced constipation. The data was presented at the American Academy of Pain Management's 20th Annual Clinical Meeting...
PR Newswire
Oct 10
Comment
PHOENIX and SAN CARLOS, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual
Stock Blog Hub
Oct 3
Comment
Recently, AstraZeneca (AZN) entered into a licensing deal with Nektar Therapeutics (NKTR) for two of its pipeline candidates, NKTR-118 and NKTR-119. With the former having completed a phase II trial for the treatment of opioid-induced...
Stock Blog Hub
Sep 22
Comment
Yesterday, AstraZeneca (AZN) entered into a licensing deal with Nektar Therapeutics (NKTR) for two of its pipeline candidates, NKTR-118 and NKTR-119. With the former having completed a phase II trial for the treatment of opioid-induced...
|
Topic
Top news source/blog that we're missing
Why do you recommend this news source?
|
||
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
NKTR AT A GLANCE
References
| ||||||
|
|
